Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-08-14FDA Approved: LAZCLUZE — Supplemental Application (Janssen Biotech, Inc.)
FDA approved Janssen's supplemental NDA for Lazertinib (LAZCLUZE), expanding its use in non-small cell lung cancer.
-
FDA approval · 2025-08-14FDA Approved: RYBREVANT — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for Rybrevant (amivantamab-vmjw) from Janssen Biotech, Inc.
-
EMA approval · 2025-08-12EMA Authorised: Naveruclif (paclitaxel) — Accord Healthcare S.L.U.
EMA authorised Naveruclif (paclitaxel) by Accord Healthcare S.L.U. for breast cancer, pancreatic cancer, and non-small cell lung cancer.
-
FDA approval · 2025-08-06FDA Approved: PEMETREXED — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for pemetrexed by Accord Healthcare Inc., enabling the generic version to be marketed under approved…
-
EMA approval · 2025-08-04EMA Authorised: Docetaxel Kabi (docetaxel) — Fresenius Kabi Deutschland GmbH
The EMA authorised Docetaxel Kabi (docetaxel) from Fresenius Kabi Deutschland GmbH for multiple cancer indications, including head and neck …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-07-25EMA Authorised: Armisarte (previously Pemetrexed Actavis) (pemetrexed diacid monohydrate) — Actavis Group PTC ehf
Armisarte (pemetrexed diacid monohydrate) has been authorised in the EU for non-small cell lung cancer and mesothelioma; Actavis Group PTC e…
-
CLINICAL_TRIALS approval · 2025-07-03Clinical Trial Update: Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
Datopotamab Deruxtecan has been approved for marketing in EGFR-mutant non-small cell lung cancer.
-
FDA approval · 2025-06-18FDA Approved: AXTLE — Supplemental Application (Avyxa Pharma, LLC)
FDA approved a supplemental application for AXTLE (pemetrexed) submitted by Avyxa Pharma, LLC.
-
CLINICAL_TRIALS approval · 2025-06-13Clinical Trial Update: Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
Amivantamab (Rybrevant) has been approved for marketing for metastatic non-small cell lung cancer, and the update includes information on a …
-
EMA approval · 2025-06-10EMA Authorised: Rozlytrek (Entrectinib) — Roche Registration GmbH
The EMA authorised Rozlytrek (entrectinib) for cancer with a conditional approval, including non-small cell lung cancer. The marketing autho…
-
EMA approval · 2025-06-10EMA Authorised: Apexelsin (paclitaxel) — Whiteoak Pharmaceutical B.V.
The EMA authorised Apexelsin (paclitaxel) for breast cancer, pancreatic cancer, and non-small cell lung cancer, with Whiteoak Pharmaceutical…
-
EMA approval · 2025-05-28EMA Authorised: Pemetrexed medac (pemetrexed) — medac Gesellschaft für klinische Spezialpräparate mbH
EMA authorised medac's pemetrexed medicine for use in non-small cell lung cancer and malignant mesothelioma.
-
FDA approval · 2025-05-15FDA Approved: PACLITAXEL PROTEIN-BOUND PARTICLES FOR INJECTABLE SUSPENSION (ALBUMIN-BOUND) — Original Application (BluePoint Laboratories)
FDA approved the original application for paclitaxel protein-bound particles for injectable suspension (albumin-bound) from BluePoint Labora…
-
FDA approval · 2025-05-14FDA Approved: EMRELIS — Original Application (AbbVie Inc.)
FDA approved EMRELIS (telisotuzumab vedotin) under the original application submitted by AbbVie. The approval pertains to a MET-targeted ant…
-
FDA approval · 2025-05-13FDA Approved: DOCETAXEL — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approves a generic docetaxel product under an original ANDA for Meitheal Pharmaceuticals Inc.
-
EMA approval · 2025-04-25EMA Authorised: Alunbrig (brigatinib) — Takeda Pharma A/S
The EMA has authorised Alunbrig (brigatinib) for non-small cell lung cancer, with Takeda Pharma A/S as the marketing authorization holder.
-
EMA approval · 2025-03-31EMA Authorised: Giotrif (afatinib) — Boehringer Ingelheim International GmbH
EMA authorised Giotrif (afatinib) for non-small cell lung cancer, decision date 31 March 2025.
-
FDA approval · 2025-03-19FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TAFINLAR (dabrafenib) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2025-03-07FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA supplemental application for TAFINLAR (dabrafenib) submitted by Novartis Pharmaceuticals Corporation to seek changes to the drug's label…
-
EMA approval · 2025-03-05EMA Authorised: Tarceva (erlotinib) — Cheplapharm Registration GmbH
Tarceva (erlotinib) has been authorised in the EU with Cheplapharm Registration GmbH as the marketing authorisation holder for non-small cel…
-
FDA approval · 2025-02-14FDA Approved: RYBREVANT — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for Rybrevant (amivantamab-vmjw) from Janssen Biotech, Inc., expanding its labeling or indications.
-
EMA approval · 2025-02-13EMA Authorised: Docetaxel Accord (docetaxel) — Accord Healthcare S.L.U.
The EMA authorised Docetaxel Accord (docetaxel) from Accord Healthcare for multiple cancer indications, including head and neck cancer, non-…
-
EMA approval · 2025-02-12EMA Authorised: Pemetrexed Fresenius Kabi (pemetrexed) — Fresenius Kabi Deutschland GmbH
The EMA authorised Pemetrexed Fresenius Kabi (pemetrexed) for use in non-small cell lung cancer and malignant mesothelioma.
-
EMA approval · 2025-01-28EMA Authorised: Augtyro (repotrectinib) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Augtyro (repotrectinib) for non-small cell lung cancer under a conditional marketing authorization. The marketing authorizati…
-
CLINICAL_TRIALS approval · 2025-01-17Clinical Trial Update: Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly's RET inhibitor selpercatinib (Retevmo) has been approved for marketing to treat cancers driven by RET activation, including non-s…